Pieris Pharmaceuticals, Inc. (PIRS) Receives Consensus Rating of “Buy” from Analysts
Shares of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) have been assigned an average recommendation of “Buy” from the six analysts that are presently covering the firm, MarketBeat.com reports. Five analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $8.25.
Several analysts have recently commented on the stock. HC Wainwright set a $9.00 price objective on shares of Pieris Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, August 11th. TheStreet downgraded shares of Pieris Pharmaceuticals from a “c-” rating to a “d-” rating in a research report on Monday, June 12th. BidaskClub downgraded shares of Pieris Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 26th. Finally, Rodman & Renshaw assumed coverage on shares of Pieris Pharmaceuticals in a research report on Tuesday, May 30th. They set a “buy” rating and a $9.00 price objective on the stock.
In related news, insider Allan Reine purchased 65,000 shares of Pieris Pharmaceuticals stock in a transaction on Thursday, August 17th. The shares were bought at an average cost of $4.82 per share, for a total transaction of $313,300.00. Following the acquisition, the insider now owns 45,000 shares in the company, valued at approximately $216,900. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director James A. Geraghty purchased 10,000 shares of Pieris Pharmaceuticals stock in a transaction on Thursday, August 17th. The stock was bought at an average price of $4.82 per share, for a total transaction of $48,200.00. Following the completion of the acquisition, the director now owns 10,000 shares in the company, valued at approximately $48,200. The disclosure for this purchase can be found here. Insiders own 4.05% of the company’s stock.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. California State Teachers Retirement System bought a new stake in Pieris Pharmaceuticals in the 2nd quarter valued at $308,000. The Manufacturers Life Insurance Company increased its holdings in Pieris Pharmaceuticals by 1,106.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,785 shares of the biotechnology company’s stock valued at $161,000 after acquiring an additional 29,150 shares during the last quarter. State Street Corp bought a new stake in Pieris Pharmaceuticals in the 2nd quarter valued at $2,377,000. Voya Investment Management LLC bought a new stake in Pieris Pharmaceuticals in the 2nd quarter valued at $100,000. Finally, Vanguard Group Inc. bought a new stake in Pieris Pharmaceuticals in the 2nd quarter valued at $526,000. Institutional investors own 50.55% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Pieris Pharmaceuticals, Inc. (PIRS) Receives Consensus Rating of “Buy” from Analysts” was published by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/09/10/pieris-pharmaceuticals-inc-pirs-receives-consensus-rating-of-buy-from-analysts.html.
Pieris Pharmaceuticals (NASDAQ:PIRS) traded up 0.95% on Tuesday, hitting $5.33. 187,351 shares of the stock traded hands. Pieris Pharmaceuticals has a 52-week low of $1.30 and a 52-week high of $6.20. The stock’s market cap is $236.16 million. The company’s 50 day moving average price is $5.17 and its 200-day moving average price is $3.98.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
Receive News & Ratings for Pieris Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.